FITCI (Frederick Innovative Technology Center, Inc.) proudly welcomes PRONAV Clinical, an internationally acclaimed early-phase clinical trial supply partner headquartered in Ireland, to its vibrant ...

BioStem made the announcement on November 20, 2024. The company indicated that the acquisition of revyve TM Antimicrobial Wound Gel reflects BioStem’s continued commitment to building a diverse ...

(the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This approval allows the ...

WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V ... rights for Kane’s revyve TM Antimicrobial Wound Gel. BioStem made the announcement on November 20, 2024.

(the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This approval allows the Company to ...

Kane Biotech Inc. announces that BioStem Technologies Inc. (BioStem ... including exclusive US distribution rights for Kane’s revyve antimicrobial wound gel. BioStem made the announcement on November ...

“We are excited to bring this much needed product to Canada,” said Marc Edwards, President & CEO. “Congratulations to the Kane Biotech team for achieving this important milestone and continue to ...

New genetic medicines for sickle cell disease were hailed as a milestone. Now researchers are working on ways to widen access ...